Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Vandana Singh

FDA Expert Panel Favors COVID-19 Boosters Targeting Omicron BA.4, BA.5 Subvariants

  • The FDA's independent experts voted to include a SARS-CoV-2 omicron component in COVID-19 vaccines that would be used for boosters in the U.S. beginning in fall 2022.
  • The panel has advised manufacturers to develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two-component (bivalent) booster vaccine.
  • The agency said that the vaccine manufacturers need not change the vaccine for primary vaccination, saying "this coming year to be a transitional period when this modified booster vaccine may be introduced."
  • Yesterday, Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTXannounced a $3.2 billion contract to supply more COVID vaccine doses to the U.S., which may include adult omicron-adapted COVID-19 vaccines, subject to the FDA authorization.
  • The FDA said vaccine manufacturers have already reported data from trials containing modified vaccines containing an omicron BA.1 component.
  • Related: Pfizer/BioNTech's Updated Omicron-Based COVID-19 Shots Show Improved Response Against Variant.
  • The agency has asked the companies to submit these data before any potential authorization of a modified vaccine containing an omicron BA.4/5 component. 
  • Manufacturers will also be asked to begin trials with modified vaccines containing an omicron BA.4/5 component, as these data will be of use as the pandemic further evolves.
  • Photo by Johaehn from Pixabay
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.